Emyria (ASX:EMD) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

EMD Panoramica delle azioni

Emyria Limited, società biotecnologica in fase clinica, è impegnata nello sviluppo di trattamenti per esigenze mediche insoddisfatte.

Informazioni sull'azienda

EMD analisi fondamentale
Punteggio fiocco di neve
Valutazione	0/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	4/6
Dividendi	0/6

Premi

Analisi del rischio

Non ha una capitalizzazione di mercato significativa ( A$15M )

Earnings have declined by 20.9% per year over past 5 years

Shareholders have been diluted in the past year

Does not have meaningful revenue (A$2M)

+ 1 più rischio

Emyria Limited Concorrenti

Ecofibre

ASX:EOF

AU$11.7m

Argent BioPharma

ASX:RGT

AU$12.1m

Firebrick Pharma

ASX:FRE

AU$10.9m

Island Pharmaceuticals

ASX:ILA

AU$8.2m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Emyria
Prezzi storici delle azioni
Prezzo attuale dell'azione	AU$0.036
Massimo di 52 settimane	AU$0.12
Minimo di 52 settimane	AU$0.034
Beta	0.86
1Variazione di 1 mese	-21.74%
Variazione a 3 mesi	-29.41%
Variazione di 1 anno	-60.87%
3Variazione a 3 anni	-80.54%
Variazione a 5 anni	n/a
Variazione dall'IPO	-75.17%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	EMD	AU Pharmaceuticals	AU Mercato
7D	-7.7%	0.9%	2.2%
1Y	-60.9%	52.4%	11.2%

Ritorno vs Industria: EMD underperformed the Australian Pharmaceuticals industry which returned 50.6% over the past year.

Rendimento vs Mercato: EMD underperformed the Australian Market which returned 10.6% over the past year.

Volatilità dei prezzi

Is EMD's price volatile compared to industry and market?
EMD volatility
EMD Average Weekly Movement	10.8%
Pharmaceuticals Industry Average Movement	10.1%
Market Average Movement	8.2%
10% most volatile stocks in AU Market	16.9%
10% least volatile stocks in AU Market	3.4%

Prezzo delle azioni stabile: EMD's share price has been volatile over the past 3 months.

Volatilità nel tempo: EMD's weekly volatility (11%) has been stable over the past year.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2018	n/a	Michael Winlo	emyria.com

Emyria Limited, società biotecnologica in fase clinica, è impegnata nello sviluppo di trattamenti per esigenze mediche insoddisfatte. L'azienda sviluppa una terapia assistita da psichedelici e un programma di scoperta di farmaci a base di MDMA. Il suo programma di sviluppo di farmaci include EMD-RX5 per il trattamento del disagio psicologico, dello stress lieve e dell'ansia.

Emyria Limited Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Emyria con la sua capitalizzazione di mercato?
EMD statistiche fondamentali
Capitalizzazione di mercato	AU$14.72m
Guadagni(TTM)	-AU$11.95m
Ricavi(TTM)	AU$1.95m

7.6x

Rapporto P/S

-1.2x

Rapporto P/E

EMD è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
EMD Conto economico (TTM)
Ricavi	AU$1.95m
Costo del fatturato	AU$2.19m
Profitto lordo	-AU$242.81k
Altre spese	AU$11.71m
Guadagni	-AU$11.95m

Ultimi guadagni dichiarati

Dec 31, 2023

Prossima data di guadagno

n/a

Utile per azione (EPS)	-0.029
Margine lordo	-12.45%
Margine di profitto netto	-612.98%
Rapporto debito/patrimonio netto	204.4%

Come si è comportato EMD nel lungo periodo?

Vedi performance storica e confronto

EMD Panoramica delle azioni

Premi

Analisi del rischio

Emyria Limited Concorrenti

ASX:EOF

AU$11.7m

ASX:RGT

AU$12.1m

ASX:FRE

AU$10.9m

ASX:ILA

AU$8.2m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

New major risk - Market cap size

Emyria Limited has filed a Follow-on Equity Offering in the amount of AUD 2.3 million.

New major risk - Financial position

New minor risk - Share price stability

Emyria Limited Appoints Greg Hutchinson as Director

Emyria Limited Announces Board Changes

Recent updates

New major risk - Market cap size

Emyria Limited has filed a Follow-on Equity Offering in the amount of AUD 2.3 million.

New major risk - Financial position

New minor risk - Share price stability

Emyria Limited Appoints Greg Hutchinson as Director

Emyria Limited Announces Board Changes

Emyria Limited has completed a Follow-on Equity Offering in the amount of AUD 1.678228 million.

Emyria Limited (ASX:EMD) completed the acquisition of The Pax Centre from Glenroyale Pty Ltd and Vivo (WA) Pty Ltd.

Emyria Limited (ASX:EMD) completed the acquisition of The Pax Centre from Glenroyale Pty Ltd and Vivo (WA) Pty Ltd.

Full year 2023 earnings released: AU$0.018 loss per share (vs AU$0.027 loss in FY 2022)

Emyria Limited, Annual General Meeting, Nov 16, 2023

New minor risk - Financial data availability

Emyria Limited Announces Strategic Board Transition

Emyria Limited (ASX:EMD) signed an agreement to acquire The Pax Centre from Glenroyale Pty Ltd for AUD 1.7 million.

Emyria Limited Secures Clinical-Grade MDMA Supply for Aust Patients

Emyria Limited Expands MDMA Programs Following Landmark TGA Decision

Will Emyria (ASX:EMD) Spend Its Cash Wisely?

Emyria Limited Announces Commencement of First Dosing for Pivotal EMD-RX5 Phase 3 Trial

Emyria Limited Announces Its Acceptance into the Preclinical Screening Platform for Pain Program

Less than half of directors are independent

Emyria Limited and The University of Western Australia Expands Unique MDMA

Emyria Expands Clinical Sites for EMD-RX5 Phase 3 Trial

Emyria Limited, Annual General Meeting, Oct 25, 2022

Full year 2022 earnings released: AU$0.027 loss per share (vs AU$0.022 loss in FY 2021)

Emyria Limited Receives Ethics Approval for Pivotal EMD-RX5 Phase 3 Trial

Emyria Limited Announces Initiation of Human Cell-Line Preclinical Studies to Advance Its Mdma-Inspired Drug Discovery Partnership with the University of Western Australia

Emyria Limited Announces Positive Progress of its Preclinical MDMA Analogue Medicine Program

Emyria Limited Reports Positive Phase 1 Trial Data for EMD-RX5 Indicating Ideal Bioavailability, Safety and Tolerability Among 12 Healthy and Demographically Diverse Volunteer Subjects

We're Hopeful That Emyria (ASX:EMD) Will Use Its Cash Wisely

Emyria Limited Receives Further Positive MDMA Analogue Screening Results

Less than half of directors are independent

Emyria Limited Announces EMD-RX5 Dosing to Complete for Phase 1 Clinical Trial

Emyria Limited Commences Dosing for EMD-RX5 Phase 1 Human Clinical Trial

Emyria Limited Commences for the EMD-RX5 Clinical Development Program

Emyria Limited Ethics Approval Receives for EMD-RX5 Phase 1 Study

Emyria Limited Announces Substantial Expansion of Proprietary MDMA Analogue Library Being Created with the University of Western Australia

Emyria Limited Announces Phase 1 Clinical Trials to Commence for Its Leading Ultra-Pure CBD Drug Candidate, Referred to as EMD-RX5

Emyria Limited announced that it expects to receive AUD 5 million in funding from Tattarang Pty Ltd

Here's Why We're Not Too Worried About Emyria's (ASX:EMD) Cash Burn Situation

Full year 2021 earnings released: AU$0.022 loss per share (vs AU$0.03 loss in FY 2020)

Emyria Limited Provides Novel Mdma Analogue Screening Program Advanced Update

Full year 2021 earnings released: AU$0.022 loss per share (vs AU$0.03 loss in FY 2020)

Emyria Executes Pure CBD Agreement with Altasciences to Accelerate FDA and TGA Cannabinoid Registration Programs

Emyria Advances EMD-004 Program Towards Registration

We Think Emyria (ASX:EMD) Needs To Drive Business Growth Carefully

Emyria Limited and Mind Medicine Australia Launch MDMA-Assisted Therapy Program for PTSD

Will Emyria (ASX:EMD) Spend Its Cash Wisely?

First half 2021 earnings released: AU$0.01 loss per share (vs AU$0.016 loss in 1H 2020)

Emyria Limited Announces the Appointment of Dr. Karen Smith to Chair the Company's Strategic Advisory Board

New 90-day high: AU$0.23

Emyria Limited Wins Digital Health Monitoring Grant with UWA

Emyria Limited Appoints Dr Richard Magtengaard, to Its Medical Advisory Board

Emyria Limited to Pursue Registration of EMD-003 with Australia's Therapeutic Goods Administration in 2021

Emyria Limited has completed a Follow-on Equity Offering in the amount of AUD 1.2 million.

Emyria Limited Launches Drug Development Program Based on RWE

Emyria Limited Partners with Mind Medicine Australia

Need To Know: Emyria Limited (ASX:EMD) Insiders Have Been Buying Shares

Executive Chairman recently bought AU$61k worth of stock

Emyria Limited Enters Data Deal with Zelira to Support Autism Trial